Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: data up to three years.

Marco Miniotti Simone RiberoLuca MastorinoMichela OrtoncelliFederica GelatoMariagiulia BailonJacopo TrioniBeatrice StefanPietro QuaglinoPaolo Leombruni

Published in: Experimental dermatology (2023)

Long-term improvement in the psychological outcome of moderate-to-severe AD patients continuously treated with Dupilumab is confirmed up to 3 years, supporting its wide use in this population. Between-subject differences in the psychological outcome irrespective of clinical response observed in this study foster the biopsychosocial approach in the clinical management of these patients.

Keyphrases

atopic dermatitis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
high intensity
physical activity
machine learning
sleep quality
patient reported outcomes
electronic health record
deep learning